LYEL Stock Cash Flow Statements

Lyell Immunopharma Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Lyell Immunopharma Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30

cash flows from operating activities
net income	-42,684,000	-52,195,000	-191,935,000	-44,583,000	-45,809,000	-60,667,000	-52,930,000	-50,853,000	-63,890,000	-66,959,000	-8,397,000	-70,254,000	-36,323,000	-68,144,000	-83,706,000	-48,875,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	5,004,000	6,024,000	8,083,000	7,622,000	8,284,000	9,155,000	8,463,000	10,516,000	14,223,000	13,882,000	18,363,000	19,123,000	22,410,000	22,028,000	21,178,000	13,042,000
depreciation and amortization expense	3,135,000	3,441,000	5,026,000	4,680,000	4,901,000	5,024,000	5,057,000	5,104,000	5,062,000	5,027,000	5,041,000	4,621,000
loss on property and equipment disposals	2,468,000	1,291,000	924,000	402,000	0	15,000	437,000	642,000				13,000
net amortization and accretion on marketable securities	-1,165,000	-1,725,000	-2,965,000	-3,587,000	-3,762,000	-4,367,000	-3,384,000	-2,287,000	-2,075,000	-1,850,000	-1,208,000	-428,000
change in fair value of contingent consideration payable	-864,000	-1,211,000
non-cash lease income	-806,000	-710,000	-607,000	-612,000	-606,000	-373,000	-529,000	-528,000	-523,000	-293,000			-441,000	-214,000
impairment of long-lived assets
change in fair value of success payment liabilities	-115,000	-125,000	-496,000	-103,000	-1,534,000	968,000	529,000	-2,706,000	1,105,000	-1,708,000	-7,307,000	2,441,000	3,587,000	-3,851,000	-15,630,000	110,000
gain on marketable equity security	2,000	26,000	17,000	102,000
impairment of other investments			0	0	0	13,001,000	0	0	2,923,000	10,000,000	0
changes in operating assets and liabilities:
prepaid expenses, other current assets and other assets	2,796,000	2,000,000	3,636,000	-1,615,000	-841,000	595,000	3,148,000	-664,000	1,049,000	-408,000	-1,296,000	-681,000	406,000	-397,000
accounts payable	-231,000	-1,654,000	-2,036,000	-568,000	-517,000	-113,000	425,000	-1,410,000	380,000	2,069,000	-526,000	23,000	-1,767,000	2,937,000	99,000	-988,000
accrued liabilities and other current liabilities	-3,330,000	-9,788,000	-1,254,000	3,094,000	516,000	-3,606,000	-1,739,000	4,612,000	2,268,000	-5,860,000	5,373,000	1,323,000	-766,000	-6,393,000	-6,250,000
other non-current liabilities	-111,000	-112,000	-312,000	126,000	-112,000	-113,000	-112,000	-112,000	-113,000	-112,000	-114,000	-113,000	-113,000	-113,000	-446,000
net cash from operating activities	-34,458,000	-54,738,000	-47,242,000	-35,042,000	-38,094,000	-42,016,000	-40,635,000	-37,686,000	-39,161,000	-46,212,000	-40,267,000	-37,103,000	-44,333,000	-47,852,000	-33,173,000	-25,532,000
capex	-314,000	-91,000	77,000	-86,000	-501,000	190,000	2,000	-226,000	-1,295,000	-1,138,000	-6,820,000	-2,781,000	-3,724,000	-9,626,000	-11,095,000	-12,746,000
free cash flows	-34,772,000	-54,829,000	-47,165,000	-35,128,000	-38,595,000	-41,826,000	-40,633,000	-37,912,000	-40,456,000	-47,350,000	-47,087,000	-39,884,000	-48,057,000	-57,478,000	-44,268,000	-38,278,000
cash flows from investing activities
purchases of property and equipment	-168,000	-246,000	-44,000	-59,000	-331,000	-30,000	-25,000	-195,000	-933,000	-1,533,000	-4,582,000	-2,791,000	-7,170,000	-9,733,000	-10,268,000	-11,599,000
purchases of marketable securities	-80,701,000	-84,411,000	-38,802,000	-131,430,000	-116,464,000	-108,011,000	-256,785,000	-78,280,000	-33,255,000	-108,560,000	-59,669,000	-160,792,000	-89,659,000	-96,196,000	-133,924,000	-275,311,000
maturities of marketable securities	93,516,000	154,123,000	123,697,000	133,407,000	161,802,000	130,035,000
net cash from investing activities	12,647,000	69,466,000	53,505,000	1,918,000	45,007,000	21,994,000	-100,690,000	99,672,000	152,912,000	32,154,000	46,648,000	-57,085,000	25,019,000	-26,122,000	-73,902,000	-144,874,000
cash flows from financing activities
proceeds from exercise of stock options			-1,000	0	52,000	103,000	151,000	72,000			325,000	5,127,000	1,570,000	2,555,000	7,399,000	529,000
proceeds from employee stock purchase plan			438,000	0			731,000	0			632,000	0
taxes paid related to net share settlement of equity awards		1,000	0	0	0	-76,000	-123,000	-215,000	-50,000	-69,000	-94,000
net cash from financing activities	183,000	1,000	437,000	0	862,000	27,000	759,000	-143,000	1,196,000	-69,000	863,000	4,760,000	2,457,000	2,555,000	7,399,000	-531,000
net decrease in cash, cash equivalents and restricted cash						-19,995,000				-14,127,000
cash, cash equivalents and restricted cash at beginning of period	0	107,287,000	0	0	0	145,931,000	0	0	0	123,834,000	0	0	0	294,294,000	0	0
cash, cash equivalents and restricted cash at end of period	-21,628,000	122,016,000	6,700,000	-33,124,000	7,775,000	125,936,000	-140,566,000	61,843,000	114,947,000	109,707,000	7,244,000	-89,428,000	-16,857,000	222,875,000	-99,676,000	-170,937,000
represented by:
cash and cash equivalents	-21,524,000	120,328,000	5,298,000	-33,125,000	7,774,000	125,650,000	-140,567,000	61,842,000	114,946,000	109,426,000	7,243,000	-89,428,000	-16,857,000	222,596,000	-99,676,000	-170,937,000
restricted cash	-104,000	1,688,000	1,402,000	1,000	1,000	286,000	1,000	1,000	1,000	281,000	1,000	0	0	279,000	0	0
total	-21,628,000	122,016,000	6,700,000	-33,124,000	7,775,000	125,936,000	-140,566,000	61,843,000	114,947,000	109,707,000	7,244,000	-89,428,000	-16,857,000	222,875,000	-99,676,000	-170,937,000
supplemental cash flow information
cash paid for amounts included in the measurement of lease liabilities	3,157,000	3,095,000	3,018,000	2,898,000	2,892,000	2,659,000	2,815,000	2,815,000	2,809,000	2,406,000	2,734,000	2,737,000	2,727,000	2,672,000	2,888,000	2,759,000
non-cash investing and financing activities:
purchases of property and equipment included in accounts payable and accrued liabilities	-146,000	155,000	121,000	-27,000	-170,000	220,000	27,000	-31,000	-362,000	395,000	-2,238,000	10,000	3,446,000	107,000	-827,000	-1,147,000
net increase in cash, cash equivalents and restricted cash		14,729,000	6,700,000	-33,124,000			-140,566,000	61,843,000			7,244,000	-89,428,000	-16,857,000	-71,419,000	-99,676,000	-170,937,000
acquired ipr&d expense
change in fair value of equity warrant											0
gain on other investments
deferred revenue											-48,354,000	1,000	-35,742,000	-558,000	-2,811,000	-2,640,000
operating lease liabilities, non-current											1,524,000	1,196,000	0	2,135,000
acquisition of assets, net of cash acquired
cash received for amounts related to tenant improvement allowances											1,523,000	1,196,000	0	2,042,000	2,232,000	5,663,000
issuance of common stock related to the purchase of the ipr&d asset on closing date
contingent consideration payable related to the purchase of the ipr&d asset on closing date
acquisition of pact series d convertible preferred shares
remeasurement of operating lease right-of-use asset for lease modification											2,000	18,000	6,000	5,000
gain on marketable equity securities						-1,535,000
gain on net operating lease liability disposal
sales and maturities of marketable securities							156,120,000	178,147,000	187,100,000	142,247,000	110,899,000	106,498,000	121,848,000	79,807,000	70,330,000	142,036,000
proceeds from initial public offering, net of issuance costs															0	-1,060,000
conversion of convertible preferred stock to common stock upon closing of initial public offering															0	0
lease expense, net of gain on lease remeasurement
gain on property and equipment disposals
expense in connection with asset acquisition
purchases of other investments
proceeds from issuance of convertible preferred stock, net of issuance costs
payments for the repurchase of common stock
payments for the repurchase of convertible preferred stock
operating lease right-of-use assets obtained in exchange for lease obligations
other investments received for sale of assets
non-cash lease expense																-405,000
change in fair value of warrants													14,000	-28,000	57,000	42,000
sales of property and equipment																0
deferred offering costs included in accounts payable and accrued liabilities
depreciation and amortization														4,187,000	4,565,000	4,091,000
net amortization or accretion on marketable securities														475,000	467,000	552,000
loss on property equipment and disposals														84,000
non-cash expense in connection with asset acquisition
loss on remeasurement of convertible preferred stock tranche liabilities
expense in connection with equity issuances
prepaid expenses and other assets															-176,000
non-cash deemed dividends on convertible preferred stock
payments for the repurchase of preferred stock
remeasurement of operating lease right of use asset for lease modification																-228,000
other
prepaid expense and other assets
accrued liabilities and other liabilities

We provide you with 20 years of cash flow statements for Lyell Immunopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Lyell Immunopharma stock. Explore the full financial landscape of Lyell Immunopharma stock with our expertly curated income statements.

The information provided in this report about Lyell Immunopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.